Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

METRELEPTIN for Hypertriglyceridaemia: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 6 adverse event reports in the FDA FAERS database where METRELEPTIN was used for Hypertriglyceridaemia.

Most Reported Side Effects for METRELEPTIN

Side Effect Reports % Deaths Hosp.
Therapy cessation 94 8.3% 7 42
Product dose omission issue 88 7.8% 2 22
Weight decreased 88 7.8% 2 20
Blood glucose increased 77 6.8% 0 21
Drug ineffective 69 6.1% 3 15
Therapy interrupted 65 5.7% 2 35
Nausea 57 5.0% 2 22
Off label use 51 4.5% 8 23
Blood triglycerides increased 49 4.3% 0 19
Treatment noncompliance 49 4.3% 4 24
Weight increased 45 4.0% 0 9
Decreased appetite 43 3.8% 2 12
Injection site pain 42 3.7% 1 4
Maternal exposure during pregnancy 41 3.6% 0 1
Hypoglycaemia 40 3.5% 2 12

Other Indications for METRELEPTIN

Lipodystrophy acquired (477) Congenital generalised lipodystrophy (394) Product used for unknown indication (97) Familial partial lipodystrophy (58) Partial lipodystrophy (51) Acquired generalised lipodystrophy (36) Lipoatrophy (16) Non-alcoholic steatohepatitis (9) Diabetes mellitus (6)

Other Drugs Used for Hypertriglyceridaemia

FENOFIBRATE (517) ATORVASTATIN (117) OMEGA-3-CARBOXYLIC ACIDS (116) GEMFIBROZIL (112) ICOSAPENT ETHYL (98) EVOLOCUMAB (70) OMEGA-3-ACID ETHYL ESTERS (58) ROSUVASTATIN (54) ALIROCUMAB (51) OMEGA-3 FATTY ACIDS (43)

Related Pages

METRELEPTIN Full Profile All Hypertriglyceridaemia Drugs METRELEPTIN Demographics METRELEPTIN Timeline